Most pages about mazdutide get its status wrong in one of two directions. Some treat it as an unapproved research chemical. Others imply you can just get it. Neither is right, and the geography is the whole point.
Is mazdutide approved?
Yes — in China. Mazdutide was approved there in 2025 for weight management, and later for type 2 diabetes, under the brand name Xinermei. It's developed by Innovent Biologics under licence from Eli Lilly. That's a real regulatory approval based on real Phase 3 trials.
It is not approved by the FDA in the US, the EMA in Europe, or most other regulators. So if you're outside China, it isn't a medicine a doctor can prescribe you — not because it's shady, but because your country's regulator hasn't reviewed it.
Semaglutide, by contrast, is approved across the US, Europe, and most of the world (Wegovy for weight management, Ozempic for type 2 diabetes).
What's the actual difference?
Both are peptides — short chains of amino acids, the tiny building blocks that make up protein. Both are weekly injections. The difference is how many signals they switch on.
- Semaglutide targets one: GLP-1, the gut hormone that tells your brain you're full.
- Mazdutide targets two: GLP-1 plus glucagon, a signal that affects how your body burns energy. It's modelled on oxyntomodulin, a hormone your own gut already releases after a meal that happens to hit both.
The head-to-head
| Factor | Mazdutide | Semaglutide |
|---|---|---|
| What it is | A dual agonist peptide (GLP-1 + glucagon), lab codes IBI362 / LY3305677 | A GLP-1 peptide — the drug in Ozempic and Wegovy |
| Approved? | China only (2025). Not approved by the FDA, EMA, or most regulators | Yes — FDA, EMA and most major regulators |
| How it's taken | Injected under the skin, once weekly | Injected under the skin, once weekly (an oral version also exists) |
| What trials showed | Phase 3 GLORY-1 and GLORY-2 showed meaningful weight loss versus placebo — almost all participants were in China | Phase 3 STEP 1 showed about 14.9% average body-weight loss over 68 weeks versus about 2.4% on placebo, across multiple countries |
| Main side effects | Mostly gut-related — nausea, vomiting, diarrhoea | Mostly gut-related — nausea, vomiting, diarrhoea; carries a boxed warning |
| Banned in sport? | Not a WADA-prohibited substance, but check current rules with your governing body | Not a WADA-prohibited substance, but check current rules with your governing body |
Which one works better?
Genuinely unsettled — and anyone claiming otherwise is ahead of the data.
Head-to-head trials do exist. DREAMS-3 compared mazdutide against semaglutide in Chinese adults with early type 2 diabetes and obesity, and GLORY-3 is comparing them in people with fatty liver disease. But at the time of writing, only the trial *designs* have been published, not the results. So we know the question is being asked properly; we don't yet have the answer.
One more thing worth flagging honestly: mazdutide's Phase 3 evidence comes almost entirely from trials in China. That's good, rigorous evidence — it just hasn't been tested as widely across different populations as semaglutide has.
Which is safer?
Both cause mainly gut trouble — nausea, vomiting, diarrhoea, especially early on. Semaglutide has been used by far more people, in far more countries, for far longer, which means rare problems have had more chances to show up and be catalogued. That's not a claim that mazdutide is riskier; it's a claim that we simply know more about semaglutide.
What's true
- Mazdutide is genuinely approved — in China, since 2025
- Mazdutide is not approved by the FDA, the EMA, or most other regulators
- Semaglutide is approved across the US, Europe, and most of the world
- Mazdutide hits two signals (GLP-1 and glucagon); semaglutide hits one
What's a myth
- 'Mazdutide is an unapproved research chemical' — it's an approved medicine, just not where you probably live
- 'Mazdutide beats semaglutide' — the head-to-head trial results haven't been published
- 'You can buy the approved Chinese drug online' — what's sold isn't that product, and can't be verified
Which should you ask a doctor about?
Outside China, there's only one of these on the table, and that's semaglutide — mazdutide simply isn't a prescribing option where it hasn't been approved. Inside China, both are, and a doctor there weighs your history and what you tolerate. Either way, the geography answers the question before the pharmacology does.
The honest verdict
Semaglutide is the globally approved, deeply studied option. Mazdutide is a legitimately approved medicine with strong Phase 3 data — inside one country. It's an interesting drug with a real evidence base, not a research chemical and not a shortcut. If you're outside China, the practical answer today is semaglutide via a doctor, not mazdutide via a website.
What this does not mean
- This doesn't mean mazdutide is unapproved or fake — it's an approved medicine in China, just not where most readers live.
- This doesn't mean mazdutide is worse than semaglutide — the head-to-head trial results simply haven't been published yet.
- This doesn't mean you can source the approved Chinese product online — what's sold grey-market isn't that product and can't be verified.
- This is general information, not medical advice. A doctor decides which medicine, if any, fits your situation.